Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago,
enormous progress has been made in stem cell biology and regenerative medicine. Human …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected
source for cell-based therapies for Parkinson's disease (PD). The regulatory criteria for the …

Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to
treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively …

The discovery of somatic cell nuclear transfer proved that somatic cells can carry the same
genetic code as the zygote, and that activating parts of this code are sufficient to reprogram …

Human pluripotent stem cells show considerable promise for applications in regenerative
medicine, including the development of cell replacement paradigms for the treatment of …

Considerable progress has been made in generating fully functional and transplantable
dopamine neurons from human embryonic stem cells (hESCs). Before these cells can be …

Modeling Parkinson's disease (PD) using advanced experimental in vitro models is a
powerful tool to study disease mechanisms and to elucidate unexplored aspects of this …

Stem cell treatments for neurodegenerative diseases are expected to reach clinical trials
soon. Most of the approaches currently under development involve transplantation of …

The banking of human leukocyte antigen (HLA)-homozygous-induced pluripotent stem cells
(iPSCs) is considered a future clinical strategy for HLA-matched cell transplantation to …